Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9531 in type 2 diabetes inadequately controlled with basal insulin
NCT07060456Phase 3Recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Jul 2025
- Primary completion
- Feb 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HRS9531 in type 2 diabetes mellitus (T2DM), sponsored by Fujian Shengdi Pharmaceuticals. Started Jul 2025; status: recruiting.
02
Drugs
HRS9531
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07060456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07060456.